GlassScriptPhysician profile
Bhaskar Sahay
NPI 1568405587
$5,224.70
in general payments reported to CMS, 2019-2025
23 companies · $760 in 2025
The $760 reported for 2025 was more than what 89% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $821 · 2021: $840 · 2022: $875 · 2023: $702 · 2024: $688 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,041.96 | 2019-2025 | Rinvoq, Humira |
| Amgen INC. | $703.60 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ani Pharmaceuticals, INC. | $459.33 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $400.41 | 2020-2025 | Acthar |
| Ucb, INC. | $317.42 | 2019-2025 | Bimzelx, Cimzia |
| Astellas Pharma US INC | $237.88 | 2019-2023 | |
| Lilly USA, LLC | $219.34 | 2020-2023 | Taltz |
| Janssen Biotech, INC. | $182.73 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $115.88 | 2021-2025 | Airsupra, Saphnelo |
| Novartis Pharmaceuticals Corporation | $113.48 | 2019-2022 | |
| Pfizer INC. | $74.87 | 2020-2022 | |
| Organon LLC | $67.80 | 2022-2024 | Hadlima, Renflexis |
| Endogastric Solutions, INC | $45.06 | 2019 | |
| Viatris Specialty LLC | $42.31 | 2025 | Yupelri |
| Genentech USA, INC. | $36.77 | 2024 | Actemra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $32.03 | 2021-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $28.86 | 2020-2021 | |
| Sandoz INC. | $25.08 | 2023 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $22.43 | 2019 | |
| Fresenius Kabi USA, LLC | $16.88 | 2024 | Idacio |
| Celgene Corporation | $14.83 | 2019 | |
| Genzyme Corporation | $14.60 | 2020 | |
| Pacira Therapeutics, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhaskar Sahay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.